IMMUNOBIOLOGY OF PANCREATIC ISLET XENOGRAFTING
胰岛异种移植的免疫生物学
基本信息
- 批准号:2466376
- 负责人:
- 金额:$ 18.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1993
- 资助国家:美国
- 起止时间:1993-01-01 至 2002-12-31
- 项目状态:已结题
- 来源:
- 关键词:MHC class II antigen SCID mouse T lymphocyte antigen presenting cell apoptosis athymic mouse cellular immunity cytolysins gene targeting genetically modified animals helper T lymphocyte inflammation interferon gamma laboratory rat leukocyte activation /transformation leukocyte adhesion molecules monoclonal antibody pancreatic islet transplantation polymerase chain reaction pore forming protein tissue /cell culture tissue donors transplant rejection transplantation immunology xenotransplantation
项目摘要
DESCRIPTION: (Adapted from the applicant's abstract) The goal of the
proposed research is to study the basis of T cell-mediated immune
recognition of xenogeneic cellular grafts, using islets of Langerhans as a
relevant model system. Data obtained during the funding period strongly
suggests that the prevalent mode of xenogenic islet recognition is through
the indirect pathway of antigen recognition by recipient's CD4+ T
lymphocytes.
In Specific Aim I a, several immunodeficient mice will be used to determine
the mechanisms of CD4+ T lymphocyte-dependent xenoreactivity towards rat
islets. The notion that islet xenografts survive in nude and SCID
recipients strongly suggests that, it least in murine recipients, rejection
of such grafts is dependent on T cells. Furthermore, evidence was obtained
during the first funding period that such cellular response is CD4+ T
cell-dependent in vivo. The first goal of this proposal is to analyze the
role of molecules involved in target cell destruction in xenograft rejection
via direct lysis (perforin), via induction of apoptosis (Fas L) and by
mediation of inflammation (IFN-g). Perforin deficient mice (PKO), Fas L
deficient mice (gld/gld) and IFN-g deficient mice will be used as donors of
CD4+ T cells, which will be transferred into RAG1-/- recipients. RAG 1-/-
(T and B cell deficient, not as leaky as SCID mice) recipients will be
previously transplanted with rat islets. The hypothesis tested by this
series of experiments is that CD4 T cell-mediated rejection of xenogeneic
islets requires triggering of inflammation, but it does not require the
presence of intact cell-cytotoxicity mediating molecules. Therefore the
expected results (supported by preliminary findings) are that PKO CD4 cells
will induce rat islet rejection in times similar to those of WT CD4 cells,
while IFN-g-deficient CD4 cells will be significantly less efficient in
mediating graft rejection.
While the pivotal role of CD4+ T cells in xenogeneic islet rejection has
been established, it can not be formally ruled out that non T cell-mediated
effector mechanisms might contribute (partially or entirely) to the observed
phenomena. Specific Aim I b is therefore set forth to explore this working
hypothesis. Specific Aim I c will test the hypothesis that CD4+ T
cell-mediated rejection of xenogeneic grafts might not require T cell
receptor-mediated interaction with the grafted target cells. Specific Aim I
d is focused on the analysis of rejection of discordant islet grafts in the
pig to mouse model system. In Specific Aim II, the P.I. proposes to
investigate the mechanisms that mediate the induction of long term survival
of xenogeneic islets grafted in mice treated with a short course of
anti-LFA-1 antibodies.
描述:(根据申请人的摘要进行了改编)
拟议的研究是研究T细胞介导的免疫的基础
使用Langerhans的胰岛识别异构细胞移植物
相关模型系统。 在资金期间获得的数据强烈
表明特种胰岛识别的普遍模式是通过
接受者CD4+ T的抗原识别的间接途径
淋巴细胞。
在特定目的I a中,将使用几只免疫缺陷的小鼠来确定
CD4+ T淋巴细胞依赖于大鼠的异种反应性的机制
胰岛。 胰岛异种移植物在裸体和scid中生存的概念
接受者强烈建议,至少在鼠的接受者中,拒绝
这种移植物的取决于T细胞。 此外,获得了证据
在第一个资金期间,这种细胞反应为CD4+ T
依赖细胞的体内。 该提案的第一个目标是分析
分子在异种移植排斥反应中涉及靶细胞破坏的作用
通过直接裂解(穿孔),通过诱导凋亡(FAS L)和
炎症的介导(IFN-G)。 穿孔蛋白缺乏小鼠(PKO),FAS L
缺乏小鼠(GLD/GLD)和IFN-G缺乏小鼠将被用作供体
CD4+ T细胞将转移到Rag1 - / - 受体中。 抹布1 - / -
(T和B细胞不足,不像SCID小鼠那样漏水)接受者将是
先前用大鼠胰岛移植。 通过此检验的假设
一系列实验是CD4 T细胞介导的异构化排斥反应
胰岛需要触发炎症,但不需要
完整的细胞毒性介导分子的存在。 因此
预期结果(由初步发现支持)是PKO CD4细胞
将在与WT CD4细胞相似的时间中诱导大鼠胰岛排斥。
而IFN-G缺陷型CD4细胞的效率将显着降低
介导移植物排斥。
虽然CD4+ T细胞在异构胰岛排斥中的关键作用具有
已建立,不能正式排除非T细胞介导的
效应器机制可能(部分或全部)对观察到的
现象。 因此,特定的目标I B是为了探索这种工作的探索
假设。 特定目的I C将检验CD4+ T的假设
细胞介导的异构移植物的排斥可能不需要T细胞
受体介导的与移植靶细胞的相互作用。 具体目的i
D专注于分析对不一致的胰岛移植物的排斥
猪到鼠标模型系统。 在特定的目标II中,P.I.求婚
研究介导诱导长期存活的机制
用短期治疗的小鼠移植的异种胰岛
抗LFA-1抗体。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ronald G Gill其他文献
Ronald G Gill的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ronald G Gill', 18)}}的其他基金
ISLET CELL RESOURCES TYPE1 DIABETES: TRANSPLANTATION: CYSTIC FIBROSIS
胰岛细胞资源 1 型糖尿病:移植:囊性纤维化
- 批准号:
7167013 - 财政年份:2005
- 资助金额:
$ 18.53万 - 项目类别:
ISLET CELL RESOURCES TYPE1 DIABETES: TRANSPLANTATION: CYSTIC FIBROSIS
胰岛细胞资源 1 型糖尿病:移植:囊性纤维化
- 批准号:
6982949 - 财政年份:2004
- 资助金额:
$ 18.53万 - 项目类别:
Correcting dysregulated peripheral tolerance in NOD mice
纠正 NOD 小鼠失调的外周耐受性
- 批准号:
6730228 - 财政年份:2003
- 资助金额:
$ 18.53万 - 项目类别:
Correcting dysregulated peripheral tolerance in NOD mice
纠正 NOD 小鼠失调的外周耐受性
- 批准号:
6806459 - 财政年份:2003
- 资助金额:
$ 18.53万 - 项目类别:
ISLET CELL RESOURCES (ICR) FAC AT THE UNIVERSITY OF *
* 大学胰岛细胞资源 (ICR) FAC
- 批准号:
7038453 - 财政年份:2001
- 资助金额:
$ 18.53万 - 项目类别:
ISLET CELL RESOURCES (ICR) FAC AT THE UNIVERSITY OF *
* 大学胰岛细胞资源 (ICR) FAC
- 批准号:
6951912 - 财政年份:2001
- 资助金额:
$ 18.53万 - 项目类别:
相似海外基金
T cell activation death & memory in alloimmune responses
T细胞活化死亡
- 批准号:
7220171 - 财政年份:2006
- 资助金额:
$ 18.53万 - 项目类别:
Use of aAPC for melanoma adoptive immunotherapy
aAPC 用于黑色素瘤过继免疫治疗
- 批准号:
6916541 - 财政年份:2004
- 资助金额:
$ 18.53万 - 项目类别:
Use of aAPC for melanoma adoptive immunotherapy
aAPC 用于黑色素瘤过继免疫治疗
- 批准号:
7099559 - 财政年份:2004
- 资助金额:
$ 18.53万 - 项目类别:
Use of aAPC for melanoma adoptive immunotherapy
aAPC 用于黑色素瘤过继免疫治疗
- 批准号:
6810352 - 财政年份:2004
- 资助金额:
$ 18.53万 - 项目类别:
Peptide antigens in CD45RBhigh CD4+T cell colitis model
CD45RBhigh CD4 T 细胞结肠炎模型中的肽抗原
- 批准号:
6623585 - 财政年份:2002
- 资助金额:
$ 18.53万 - 项目类别: